Last Update Time:
21-Mar-2025 10:16:16
ISIN:
INE987B01026
Sector:
Healthcare
Symbol:
NATCOPHARM
Natco Pharma Limited
₹827.65
₹1.55
(0.19%)
▲
Prev. Close
₹826.10
Open
₹826.10
Close
₹0.00
Range
₹786.27 - ₹869.03
High
₹837.80
Low
₹823.40
Ind. Close
₹0.00
VWAP
₹831.80
The current stock price of Natco Pharma Limited is ₹827.65, with a target price range between ₹786.27 and ₹869.03. The stock has experienced a price change of ₹1.55 (0.19%), reflecting recent market volatility.
Today's opening price was ₹826.10, while the previous close stood at ₹826.10.
The market trend suggests an uptrend, making it an attractive investment opportunity for traders seeking short-term gains.
For real-time stock market updates, live share prices, and stock analysis, stay tuned. Understanding key stock metrics like VWAP, high-low range, and market momentum can help traders make informed investment decisions.
Natco Pharma Limited Price Chart
Natco Pharma Limited Pre Open Market Overview: 21-Mar-2025
Key Metrics:
- IEP (Indicative Equilibrium Price): 826.1
- Previous Close Price: 826.1
- Change: 0.00%
- Total Traded Volume: 1,389
- Total Buy Quantity: 16,523
- Total Sell Quantity: 16,079
| Price | Buy Qty | Sell Qty |
|---|---|---|
| 823.00 | 57.00 | 0.00 |
| 824.55 | 10.00 | 0.00 |
| 825.00 | 17.00 | 0.00 |
| 825.50 | 14.00 | 0.00 |
| 826.00 | 17.00 | 0.00 |
| 826.10 | 0.00 | 183.00 |
| 827.00 | 0.00 | 50.00 |
| 827.90 | 0.00 | 50.00 |
| 828.00 | 0.00 | 51.00 |
| 828.80 | 0.00 | 50.00 |
ATO Data:
- Buy Quantity (ATO): 0
- Sell Quantity (ATO): 0
Order Book
| Bid | Qty | Ask | Qty |
|---|---|---|---|
| 827.55 | 10 | 827.65 | 47 |
| 827.50 | 31 | 827.70 | 85 |
| 827.45 | 10 | 827.75 | 1 |
| 827.25 | 4 | 827.80 | 1 |
| 827.20 | 203 | 827.85 | 9 |
Total Buy Quantity: 16523
Total Sell Quantity: 16079
Shareholding Patterns of Natco Pharma Limited
Key Trade Statistics of Natco Pharma Limited
| Trade Information | Details |
|---|---|
| Traded Volume (Lakhs) | 1.53 |
| Traded Value (₹ Cr.) | 12.70 |
| Total Market Cap (₹ Cr.) | 14,824.03 |
| Free Float Market Cap (₹ Cr.) | 7,397.12 |
| Impact cost | 0.04 |
| Quantity Traded | 787,698.00 |
| Deliverable Quantity | 497,337.00 |
| % of Quantity to Traded | 63.14 |
| Security VaR | 17.24 |
| Index VaR | N/A |
| VaR Margin | 17.24 |
| Extreme Loss Rate | 3.5 |
| Adhoc Margin | N/A |
| Applicable Margin Rate | 20.74 |
| Face Value | 2 |
Key Price Statistics of Natco Pharma Limited
The 52-week high for Natco Pharma Limited was ₹1,639.00, recorded on 12-Sep-2024. On the other hand, the 52-week low stands at ₹757.05, with the lowest value recorded on 28-Feb-2025.
The upper band for trading is ₹908.70, and the lower band is ₹743.50. The price band is 10%.
The stock's daily volatility stands at 2.65, while the annualized volatility is 50.63. The tick size for trading is ₹0.05.
| Price Information | Details |
|---|---|
| 52 Week High (12-Sep-2024) | 1,639.00 |
| 52 Week Low (28-Feb-2025) | 757.05 |
| Upper Band | 908.70 |
| Lower Band | 743.50 |
| Price Band (%) | 10 |
| Daily Volatility | 2.65 |
| Annualised Volatility | 50.63 |
| Tick Size | 0.05 |
Key Securities Statistics of Natco Pharma Limited
| Securities Information | Details |
|---|---|
| Status | Listed |
| Trading Status | Active |
| Date of Listing | 27-Dec-1995 |
| Adjusted P/E | 7.94 |
| Symbol P/E | 7.94 |
| Index | NIFTY 500 |
| Macro-Economic Sector | Healthcare |
| Sector | Healthcare |
| Industry | Pharmaceuticals & Biotechnology |
| Basic Industry | Pharmaceuticals |
Security Status of Natco Pharma Limited
| Title | Details |
|---|---|
| Board Status | Main |
| Trading Segment | Normal Market |
| Session No. | - |
| Class of Shares | Equity |
| SDD Compliance | - |
| Name of Compliance Officer | - |
Announcements of Natco Pharma Limited
| Subject | Date |
|---|---|
| Change in Directors/ Key Managerial Personnel/ Auditor/ Compliance Officer/ Share Transfer Agent | 03-Mar-2025 |
| Appointment | 03-Mar-2025 |
| Change in Management | 27-Feb-2025 |
| Change in Directors/ Key Managerial Personnel/ Auditor/ Compliance Officer/ Share Transfer Agent | 27-Feb-2025 |
| Analysts/Institutional Investor Meet/Con. Call Updates | 27-Feb-2025 |
| Analysts/Institutional Investor Meet/Con. Call Updates | 24-Feb-2025 |
| Action(s) initiated or orders passed | 21-Feb-2025 |
| Analysts/Institutional Investor Meet/Con. Call Updates | 19-Feb-2025 |
Corporate Actions of Natco Pharma Limited
| Face Value | Purpose | Ex-Date |
|---|---|---|
| 2 | Interim Dividend - Rs 1.50 Per Share | 18-Feb-2025 |
| 2 | Interim Dividend - Rs 1.50 Per Share | 27-Nov-2024 |
| 2 | Annual General Meeting | 25-Sep-2024 |
| 2 | Interim Dividend - Rs 3 Per Share | 23-Aug-2024 |
| 2 | Interim Dividend - Rs 1.25 Per Share | 26-Feb-2024 |
| 2 | Interim Dividend - Rs 1.25 Per Share | 24-Nov-2023 |
| 2 | Annual General Meeting | 25-Sep-2023 |
| 2 | Interim Dividend - Rs 7 Per Share | 22-Aug-2023 |
| 2 | Interim Dividend - Rs 1.25 Per Share | 21-Feb-2023 |
| 2 | Interim Dividend - Re 0.75 Per Share | 21-Nov-2022 |
| 2 | Annual General Meeting | 23-Sep-2022 |
| 2 | Interim Dividend - Rs 3.50 Per Share | 19-Aug-2022 |
| 2 | Interim Dividend - Rs 2 Per Share | 24-Feb-2022 |
| 2 | Interim Dividend - Rs 0.50 Per Share | 23-Nov-2021 |
| 2 | Annual General Meeting | 23-Sep-2021 |
| 2 | Interim Dividend - Rs 2 Per Share | 24-Aug-2021 |
| 2 | Interim Dividend - Re 1 Per Share | 22-Feb-2021 |
| 2 | Interim Dividend - Rs 3 Per Share | 24-Nov-2020 |
| 2 | Annual General Meeting | 09-Oct-2020 |
| 2 | Interim Dividend - Rs 1.25 Per Share | 21-Aug-2020 |
Board Meetings of Natco Pharma Limited
Financial Results of Natco Pharma Limited
Company Directory of Natco Pharma Limited
| Web Address | Office | Address | City |
|---|---|---|---|
| www.natcopharma.co.in | Registered Office | Natco House, Road No.2, Banjara Hills, | HYDERABAD |
| www.natcopharma.co.in | Transfer Agent | Venture Capital & Corporate Investments Pvt Ltd AURUM, DOOR No.4-50/P-II/57/4F & 5F, PLOT No.57 4th & 5th FLOORS, JAYABHERI ENCLAVE PHASE II GACHIBOWLI | HYDERABAD |
Insider Trading of Natco Pharma Limited
| Reg. Clause | Acq./Disp. | Sec. Value | Txn Type |
|---|---|---|---|
| 7(2) | SATYA VANI NANNAPANENI | 0 | Buy |
| 7(2) | SANJAY NANNAPANENI | 0 | Buy |
| 7(2) | TUMMALA VENKAT RAO | 3450942 | Sell |
| 7(2) | Lakshminarayana Bolisetty | 2783220 | Sell |
| 7(2) | SADA SIVA RAO. NANNAPANENI | 7336084 | Sell |
| 7(2) | TUMMALA RAHUL | 1352855 | Sell |
| 7(2) | TUMMALA RAHUL | 1223319 | Sell |
| 7(2) | AMIT SOGANI | 2426355 | Sell |
| 7(2) | SUNIL KOTARU | 2039178 | Sell |
| 7(2) | G VENKATA RAMANA | 3066041 | Sell |
| 7(3) | M SUBBA RAO | 30279976 | Sell |
| 7(2) | DHRUVA KUMAR NANNAPANENI | 936053 | Sell |
| 7(2) | N SRILAKSHMI | 14561257 | Sell |
| 7(2) | RATNAKUMAR K | 16887583 | Sell |
| 7(2) | ANILA T | 50311107 | Sell |
| 7(2) | VIDYADHARI TUMMALA | 109406211 | Sell |
| 7(2) | RATNAKUMAR K | 56136647 | Sell |
| 7(2) | PULLAREDDY MUDDASANI | 585315 | Sell |
| 7(2) | TUMMALA VENKAT RAO | 482918 | Sell |
| 7(2) | VENKATA SREENIVASABABU KURRA | 2893020 | Sell |
Annual Reports of Natco Pharma Limited
Investor Complaints of Natco Pharma Limited
Event Calendar of Natco Pharma Limited
| Purpose | Details |
|---|---|
| Results/Others | To consider among other things, the unaudited financial Results for the quarter ended June 30, 2010, convening of Annual General Meeting and related matters etc. |
| Results/Others | To consider among other things, the unaudited financial Results for the quarter ended September 30, 2010 and related matters etc. |
| Results/Dividend | To consider among other things, the unaudited financial Results for the quarter ended December 31, 2010, and to consider Interim Dividend, if any, for the financial year 2010-11 and related matters etc. |
| Results/Others | To consider among other things, approval of the annual accounts and consolidated financial results of the Company for the year ended on March 31, 2011 and related matters. |
| Results/Others | The Company had informed the Exchange that a Meeting of the Board of Directors of the Company will be held on August 12, 2011 to consider among other things, the unaudited financial Results for the quarter ended June 30, 2011, convening of Annual General Meeting and related matters etc. The Company has now informed the Exchange that in the aforesaid Board Meeting the Board of Directors will also be considering the issue of Foreign Currency Convertible Bonds (FCCBs) which are compulsorily convertible into equity shares not exceeding 30,00,000 equity shares of Rs.10/- each. Board of Directors will be considering the constitution of committee of Directors to finalise the issue price, tenure and other terms and conditions for said issue. Compensation Committee constituted by Board will be considering grant of Employee Stock Options to its employees on the same day. (Purpose Revised). |
| Results/Others | To consider among other things, the unaudited financial Results for the quarter ended June 30, 2011, convening of Annual General Meeting and related matters etc. |
| Results/Others | To consider among other things, the unaudited financial Results for the quarter ended September 30, 2011 and related matters etc. |
| Results/Dividend | To consider among other things, the unaudited financial Results for the Quarter ended December 31, 2011, to consider Interim Dividend , if any, for the financial year 2011-2012 and related matters etc. |
| Results/Others | To consider among other things, approval of the Audited Results for the quarter ending March, 2012 along with Audited Annual Accounts for the year 2011-2012 and related matters. |
| Results/Others | To consider among other things, the unaudited financial Results for the quarter ended June 30, 2012, convening of Annual General Meeting and related matters etc. |
| Results/Others | To consider among other things, the unaudited financial Results for the quarter ended September 30, 2012 and related matters etc. |
| Results/Dividend | To consider among other things, the unaudited financial Results for the quarter ended December 31, 2012, to consider Interim Dividend, if any, for the financial year 2012-13 and related matters etc. |
| Results/Others | To consider among other things, approval of the Audited Results for the quarter ending March, 2013 along with Audited Annual Accounts for the year 2012-2013 and related matters. |
| Results | To consider the audited consolidated financial statements. |
| Results/Others | To consider among other things, the unaudited financial Results for the quarter ended June 30, 2013, convening of Annual General Meeting and related matters etc. |
| Preferential issue | To consider among other things, the proposal to issue equity shares of the Company on preferential allotment basis and related matters etc. |
| Results | To consider among other things, the unaudited financial results for the quarter ending September 30, 2013 and related matters. |
| Results/Dividend | To consider among other things, the unaudited financial Results for the quarter ended December 31, 2013, to consider Interim Dividend, if any, for the financial year 2013-14 and related matters etc. |
| Results | to consider audidted financial results for the quarter ending March, 2014 and Audited Annual Accounts for the year 2013-2014 |
| Results/Others | To consider among other things, the unaudited financial Results for the quarter ended 30th June, 2014, convening of Annual General Meeting and related matters etc. Further, TRADING WINDOW for dealing in the securities of the company will be closed from 31st July, 2014 to 14th August, 2014 (both days inclusive). Trading window will be opened from 18th August, 2014. |
| Results/Others | To consider among other things, the un-audited financial Results for the quarter ended September 30, 2014 and related matters. |
| Results/Dividend | To consider among other things, the unaudited financial Results for the quarter ended December 31, 2014, to consider Interim Dividend, if any, for the financial year 2014-15 and related matters etc. |
| Results/Others | To consider the following things: 1. Approval of the unaudited financial Results for the quarter ending March, 2015 along with Audited Annual Accounts for the year 2014-2015 . 2. Approval of increase of equity investment percentage in the Company to 49% to Foreign Institutional Investors (Flls) / Foreign Portfolio Investors etc. 3. Further issue of shares or Convertible Securities of any nature in the form of Private Placement, Qualified Institutional Placement (QIP) to Foreign Institutional Investors (Fils), Qualified Institutional Buyers or any other investors etc. 4. Merger of Natco Organics limited (100% subsidiary Company) into Natco Pharma Limited 5. Consideration of Employee Stock Option Scheme under SEBI (Share Based Employee Benefits) Regulations, 2014. 6. Convening of Extraordinary General Meeting of the Members. |
| Results/Others | To consider among other things, the following items of businesses and related matters:1. Various options of raising of funds for one of the subsidiaries Timecap Overseas Ltd., Mauritius to be used for investment in Natcofarma Do Brasil Ltda, Brasil.2. Unaudited financial Results for the quarter ended June 30, 2015.3. Convening of Annual General Meeting for the financial year 2014-15.4. To issue the notice of postal ballot and evoting to shareholders for approving the Scheme of Amalgamation of Natco Organics Limited into the Company and related matters. |
| Results/Others | to consider among other things, the following:1. The un-audited Results for the quarter and half year ended September 30, 2015 and other related matters.2. To fix record date for sub-division of 1 (One) Equity Share of face value of Rs. 10/- each into 5(five) Equity Shares of Rs. 2/- Each. |
| Results/Dividend | to consider among other things, the following : 1) The unaudited financial Results for the quarter and nine months ended December 31, 2015 and related matters. 2) To consider Interim Dividend, if any, for the financial year 2015-16 and related matters etc. |
| Results | To, inter alia, consider and approve the Audited Financial Results for the Year ended March 31, 2016. |
| Results/Dividend | to consider among other things, the following items of business and related matters:1) Unaudited financial Results for the quarter ended June 30, 2016. 2) To consider Interim Dividend, if any, for the year 2016-17. 3) Convening of Annual General Meeting for the financial year 2015-16. 4) Consideration of Employee Stock Option scheme (NATSOP2016) under SEBI(Share Based Employee Benefits) regulations, 2014. |
| Results | To consider among other things, the Unaudited Financial Results for the quarter and half year ended September 30, 2016 and related matters. |
| Results/Dividend | To consider among other things, the following items of business: 1. The audited financial Results for the quarter ended December 31, 2016 and related matters. 2. To consider second Interim Dividend, if any, for the financial year 2016-17 and related matters etc. |
| Results | Inter alia, to consider and approve the Audited Financial Results for the quarter and year ended March 31, 2017 and related matters. |
| Results/Dividend | To consider, among other things, the following items of businesses and related matters: 1. Unaudited financial results for the quarter ended June 30, 2017 along with the Limited Review Report thereon. 2. To Consider Interim Dividend, if any, for the year 2017-18. 3. Convening of 34th Annual General Meeting to be held for the financial year 2016-17. 4. Consideration of Natco Employee Stock Option Scheme 2017 (NATSOP 2017) under SEBI (Share Based Employee Benefits) Regulations, 2014 |
| Results/Others | To consider, among other things, the following items of businesses and related matters: 1. Approval of the unaudited financial results, both on standalone and consolidated basis for the quarter and half-year ended September 30, 2017. 2. Approval for raising of funds through further issue of shares or convertible securities of any nature through one or more modes, including but not limited to a further public offer, rights issue, qualified institutions placement, issue of american depository receipts or global depository receipts etc. subject to such approvals as may be required. 3. Convening of Extraordinary General Meeting of the members of the Company to approve such raising of funds. |
| Results/Dividend | To consider among others things, the following items of business: 1. The unaudited financial Results for the quarter and the nine months ended December 31, 2017 and related matters. 2. To consider second Interim Dividend, if any, for the financial year 2017-18 and related matters etc. |
| Financial Results | To consider and approve the financial results for the period ended March 31, 2018 |
| Financial Results/Dividend | To consider and approve the financial results for the period ended Jun 30, 2018 and dividend |
| Financial Results/Buyback | To consider and approve the financial results for the period ended September 30, 2018 and buyback for equity shares |
| Financial Results/Dividend | To consider and approve the financial results for the period ended December 31, 2018 and dividend |
| Financial Results/Dividend/Other business matters | To consider and approve the financial results for the period ended March 31, 2019, dividend and other business matters |
| Financial Results/Dividend | To consider and approve the financial results for the period ended Jun 30, 2019 and dividend |
| Financial Results | To consider and approve the financial results for the period ended September 30, 2019 |
| Financial Results/Dividend | To consider and approve the financial results for the period ended September 30, 2019 and to consider declaration of 2nd Interim Dividend, if any, for the Financial year 2019-2020 |
| Financial Results/Dividend | To consider and approve the financial results for the period ended December 31, 2019 and dividend |
| Financial Results/Dividend | To consider and approve the financial results for the period ended March 31, 2020 and dividend |
| Financial Results | To consider and approve the financial results for the period ended Jun 30, 2020 |
| Financial Results/Dividend | To consider and approve the financial results for the period ended September 30, 2020 and second interim dividend, if any for the fy 20-21 |
| Financial Results/Dividend | To consider and approve the financial results for the period ended December 31, 2020 and dividend |
| Financial Results/Dividend | To consider and approve the financial results for the period ended March 31, 2021 and dividend |
| Financial Results/Dividend | To consider and approve the financial results for the period ended Jun 30, 2021 and dividend |
| Financial Results/Dividend | To consider and approve the financial results for the period ended September 30, 2021 and dividend |
| Financial Results/Dividend | To consider and approve the financial results for the period ended December 31, 2021 and dividend |
| Financial results | Natco Pharma Limited has informed the Exchange about Board Meeting to be held on 30-May-2022 to consider financial statements for the quarter and year ended 31st March 2022 |
| Financial Results/Dividend | To consider and approve the financial results for the period ended December 31, 2022 and to consider the third interim dividend, if any |
| Buyback | To consider buyback for equity shares |
| Financial Results | To consider and approve the financial results for the period ended March 31, 2023 |
| Financial Results/Dividend | To consider and approve the unaudited financial results for the period ended Jun 30, 2023 and interim dividend for the financial year ending 2023-24 |
| Financial Results/Dividend | To consider and approve the financial results for the period ended September 30, 2023 and Interim dividend, if any |
| Financial Results/Dividend | To consider and approve the financial results for the period ended December 31, 2023 and 3rd interim dividend for the Financial Year 2023-24, if any. |
| Financial Results | To consider and approve the financial results for the period ended March 31, 2024 |
| Financial Results/Dividend | To consider and approve the financial results for the quarter ended Jun 30, 2024 and Interim dividend for FY 2024-25, if any |
| Financial Results/Dividend | To consider and approve the un audited financial results for the period ended September 30, 2024 and 2nd Interim dividend, if any |
| Financial Results/Dividend | To consider and approve the financial results for the period ended December 31, 2024 and 3rd Interim dividend, if any |
Share Transfers of Natco Pharma Limited
Voting Results of Natco Pharma Limited
| Date of Mtg. | Mtg. Type | Resolution |
|---|---|---|
| 30-SEP-2024 | AGM | Adoption of audited Annual Financial Statements for the Financial Year 2023-24 |
| 30-SEP-2024 | AGM | Revision in the remuneration of Dr. Pavan Ganapati Bhat (DIN: 09691260) as Director & Executive Vice President (Technical Operations) of the Company |
| 30-SEP-2024 | AGM | Revision in the remuneration of Dr. D. Linga Rao (DIN: 07088404) Director and President (Tech. Affairs) of the Company |
| 30-SEP-2024 | AGM | Revision in the remuneration of Sri P.S.R.K. Prasad (DIN: 07011140) Director and Executive Vice President (Corporate Engineering Services) of the Company |
| 30-SEP-2024 | AGM | Appointment of Sri Nitin Jain (DIN 00136245) to the office of Independent Director |
| 30-SEP-2024 | AGM | Appointment of Dr. Kantipudi Suma (DIN 02734369) to the office of Independent Director |
| 30-SEP-2024 | AGM | Appointment of Sri Lakshminarayana Bolisetty (DIN 02766709) to the office of Independent Director |
| 30-SEP-2024 | AGM | Ratification of remuneration of Cost Auditors |
| 30-SEP-2024 | AGM | Appointment of Statutory Auditors |
| 30-SEP-2024 | AGM | Re-appointment of Dr. Pavan Ganapati Bhat (DIN: 09691260) as a Director liable to retire by rotation |
| 30-SEP-2024 | AGM | Re-appointment of Dr. D. Linga Rao (DIN: 07088404) as a Director liable to retire by rotation |
| 30-SEP-2024 | AGM | To confirm three interim dividends aggregating to Rs.9.50 per share paid on equity shares during the Financial Year 2023-24 as dividend for the FY 2023-24. |
| 26-MAR-2024 | Postal Ballot | To appoint Sri A.D.M. Chavali (DIN: 00374673) as Independent Director of the Company |
| 26-MAR-2024 | Postal Ballot | To reappoint Dr. Pavan Ganapati Bhat (DIN: 09691260) as Director & Executive Vice President (Technical Operations) of the Company |
| 26-MAR-2024 | Postal Ballot | To reappoint Dr. D. Linga Rao (DIN: 07088404) as Director and President (Tech. Affairs) of the Company |
| 26-MAR-2024 | Postal Ballot | To reappoint Sri P.S.R.K Prasad (DIN: 07011140) as Director and Executive Vice President (Corporate Engineering Services) of the Company |
| 26-MAR-2024 | Postal Ballot | To appoint Sri Rajeev Nannapaneni (DIN: 00183872) as Vice Chairman and Chief Executive Officer of the Company |
| 26-MAR-2024 | Postal Ballot | To appoint Sri V.C. Nannapaneni (DIN: 00183315) as Chairman & Managing Director of the Company |
| 26-MAR-2024 | Postal Ballot | To appoint Sri D. Vijaya Bhaskar (DIN:07158951) as Independent Director of the Company |
| 29-SEP-2023 | AGM | Adoption of audited Annual Financial Statements for the Financial Year 2022-23 |
FAQs on Natco Pharma Limited
Disclaimer: The information provided here is for informational purposes only and should not be considered financial advice. Please do your own research and consult with a financial professional before making any investment decisions.